99mTc-labeling studies of a modified metronidazole and its biodistribution in tumor bearing animal models

Nuclear Medicine and Biology

Volumn 30, Issue 2, 2003, Pages 127-134

  Das, Tapas ^a   Banerjee, Sharmila ^a   Samuel, Grace ^a   Sarma, H D ^a   Korde, Aruna ^a   Venkatesh, Meera ^a   Pillai, M R A ^a  

^a BHABHA ATOMIC RESEARCH CENTRE   (India)

Author keywords

99mTc; Hypoxia; Metronidazole; Tumor imaging

Indexed keywords

CARBOXYLIC ACID; CHELATING AGENT; CYSTEINE DERIVATIVE; METRONIDAZOLE; N (2' HYDROXYBENZYL)CYSTEINE; NITROIMIDAZOLE; TECHNETIUM 99M; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; DRUG DERIVATIVE; RADIOPHARMACEUTICAL AGENT; TECHNETIUM DERIVATIVE;

ARTICLE; COMPLEX FORMATION; HEPATOBILIARY SYSTEM; ISOTOPE LABELING; KIDNEY CLEARANCE; LIVER CLEARANCE; TUMOR; ANIMAL; ANTIBODY SPECIFICITY; CANCER TRANSPLANTATION; CELL CULTURE; EVALUATION; FEMALE; LYMPHOMA; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; MOUSE; SCINTISCANNING; SYNTHESIS; THYMOMA; TISSUE DISTRIBUTION;

ANIMALS; FEMALE; ISOTOPE LABELING; LYMPHOMA; METABOLIC CLEARANCE RATE; METRONIDAZOLE; MICE; NEOPLASM TRANSPLANTATION; ORGAN SPECIFICITY; RADIOPHARMACEUTICALS; TECHNETIUM COMPOUNDS; THYMUS NEOPLASMS; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED;

EID: 0037291072     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8051(02)00388-8     Document Type: Article

References (25)

1. Ballinger J.R., Min-Kee J.W., Rauth A.M. In vitro and in vivo evaluation of a technetium-99m labeled 2-nitroimidazole (BMS 181321) as marker of tumor hypoxia. J Nucl Med. 37:1996;1023-1031.
2. Ballinger J.R. Imaging hypoxia in tumors. Semn Nucl Med. 31:2001;321-329.
3. Bhattacharjee D. Role of adaptation on radiation-induced thymic lymphoma in mice. Mutat Res. 358:1996;231-235.
4. Biskupiak J.E., Grierson J.R., Rasey J.S., Martin G.V., Krohn K.A. Synthesis of an (iodovinyl)misonidazole derivative for hypoxia imaging. J Med Chem. 34:1991;2165-2168.
5. Brown J.M. Hypoxic cell radiosensitizers Where next? Int J Radiat Oncol Biol Phys. 16:1989;987-993.
6. Chapman J.D. Hypoxic sensitizers implications for radiation therapy . N Engl J Med. 301:1979;1429-1432.
7. Chapman J.D., Franko J.A., Sharplin J. A marker of hypoxic cells in tumors with potential clinical applicability. Br J Cancer. 43:1981;546-550.
8. Chapman J.D., Baer K., Lee J. Characteristics of the metabolism-induced binding of misonidazole to hypoxic mamalian cells. Cancer Res. 43:1983;1523-1528.
9. 186/188Re] Rhenium-ethylene dicysteine (Re-EC) preparation and evaluation for possible use in endovascular brachytherapy . Nucl Med Biol. 27:2000;189-197.
10. Edwards D.L. Nitroimidazole drugs- action and resistance mechanisms 1. Mechanisms of action . J Antimicrob Chemother. 31:1993;9-20.
11. Gary L.H., Conger A.D., Ebert M., Hornsey S., Scott O.C.A. Concentration of oxygen dissolved in tissues at time of irradiation as a factor in radiotherapy. Br J Radiol. 26:1953;638-648.
12. Grunbaum Z., Freauff S.J., Krohn K.A., Wilbur D.S., Magee S., Rasey J.S. Synthesis and characterization of congeners of misonidazole for imaging hypoxia. J Nucl Med. 28:1987;68-75.
13. 18F-labeled misonidazole potential in vivo markers of hypoxic tissues . Appl Radiat Isot. 37:1986;599-605.
14. 82Br]bromomisonidazole. Int J Nucl Med Biol. 10:1983;205-210.
15. 18F]-fluoromisonidazole. Int J Radiat Oncol Biol Phys. 22:1991;199-212.
16. Mannan R.H., Somayaji V.V., Lee J., Mercer J.R., Chapman J.D., Wiebe L.I. Radioiodinated 1-(5-iodo-5′-deoxy-D-arabinofuranosyl)-2-nitroimidazole (iodoazomycin arabinoside:IAZA) a novel marker of tissue hypoxia . J Nucl Med. 32:1991;1764-1770.
17. 99mTc-labeled 2-nitroimidazole for imaging hypoxia in tumors. J Nucl Med. 41:2000;169-176.
18. Moulder J.E., Rockwell S. Tumor hypoxia its implication on cancer therapy . Cancer Metastasis Rev. 5:1987;313-341.
19. Nunn A., Linder K., Strauss H.W. Nitroimidazoles and imaging hypoxia. Eur J Nucl Med. 22:1995;265-280.
20. 123I-iodoazomycin arabinoside preliminary report of a clinical study . Br J Cancer. 65:1992;90-95.
21. Pauwels E.K.J., McCready V.R., Stoot J.H.M.B., Deurzen D.F.P.V. The mechanism of accumulation of tumor-localizing radiopharmaceuticals. Eur J Nucl Med. 25:1998;277-305.
22. 99mTc complexes of modified cysteine ligands and bifunctional chelating agents. Nucl Med Biol. 26:1999;555-561.
23. Rasey J.S., Krohn K.A., Freauff S. Bromomisonidazole, synthesis and characterisation of a new radiosensitiser. Radiat Res. 91:1982;542-554.
24. Strauss A.W., Nunn A., Linder K. Nitroimidazoles for imaging hypoxic myocardium. J Nucl Cardiol. 2:1995;437-445.
25. Verghese A.J., Whitmore G.F. Binding of cellular macromolecules as a possible mechanism for the cytotoxicity of misonidazole. Cancer Res. 40:1980;2165-2168.